BrainsWay Ltd.
BWAYHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, BrainsWay Ltd. (BWAY) is listed under Medical Devices. With a market capitalization of $569.3M, it sits in small-cap territory. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Market Cap
$569.3M
Beta
0.08
P/E (TTM)
61.57
P/E (Fwd)
27.95
EPS (TTM)
$0.23
EPS (Fwd)
$0.51
ROE
12.8%
ROA
4.0%
Cash
$62.1M
Total Debt
$7.1M
Free CF
-$6.2M
52W Change
77.6%
Annual Financials
Cash vs Debt
Where BWAY stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BWAY finished 0.76% below its 150-day moving average ($14.39) and 8.18% above its 200-day moving average ($13.20). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BWAY overbought or oversold?
At the September 3, 2026 close, BWAY's RSI(14) was 24.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $62.1M in cash comfortably exceeding the $7.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$6.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of 12.8% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.0% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $27.2M (2022) to $52.2M (2025), reflecting a 92% increase over the period.
The relatively low beta of 0.08 suggests BWAY is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, BWAY has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. At over 50x earnings, BWAY carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. No single metric tells the full story. Reviewing BWAY's risk profile alongside its fundamentals and technical indicators provides a more complete picture.